Which biotech stocks should investors take a hard look at buying now? Health care analyst Max Macaluso sat down with Fool.com contributor Keith Speights recently to find out which stocks he likes in the biotech sector. Two big biotechs that Keith recommends are Biogen Idec and Celgene .
Biogen and Celgene are both established companies with solid revenue. Biogen's multiple sclerosis drugs position it as a leader in that market. Likewise, Celgene's Revlimid stands at the top in treating multiple myeloma and myelodysplastic syndromes. Biogen and Celgene also count promising new drugs that have the potential to drive revenue even higher.
Both of these biotechs are red hot these days. Biogen shares are up over 33% so far in 2013. Celgene is up even more, rising 50% year-to-date. In this video interview, Max talks with Keith about why these hot biotech stocks should continue to do well over the long run.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today simply click here now.
The article 2 Hot Biotech Stocks to Buy Now originally appeared on Fool.com.
Fool contributor Keith Speights and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.